A Novel T Cell-Engaging Bispecific Antibody for Treating Mesothelin-Positive Solid Tumors.

Biomolecules
Aerin YoonYangmi Lim

Abstract

As mesothelin is overexpressed in various types of cancer, it is an attractive target for therapeutic antibodies. T-cell bispecific antibodies bind to target cells and engage T cells via binding to CD3, resulting in target cell killing by T-cell activation. However, the affinity of the CD3-binding arm may influence CD3-mediated plasma clearance or antibody trapping in T-cell-containing tissues. This may then affect the biodistribution of bispecific antibodies. In this study, we used scFab and knob-into-hole technologies to construct novel IgG-based 1 + 1 MG1122-A and 2 + 1 MG1122-B bispecific antibodies against mesothelin and CD3ε. MG1122-B was designed to be bivalent to mesothelin and monovalent to CD3ε, using a 2 + 1 head-to-tail format. Activities of the two antibodies were evaluated in mesothelin-positive tumor cells in vitro and xenograft models in vivo. Although both antibodies exhibited target cell killing efficacy and produced regression of xenograft tumors with CD8+ T-cell infiltration, the antitumor efficacy of MG1122-B was significantly higher. MG1122-B may improve tumor targeting because of its bivalency for tumor antigen. It may also reduce systemic toxicity by limiting the activation of circulating T cells. Thus, ...Continue Reading

References

Jan 6, 2012·Proceedings of the National Academy of Sciences of the United States of America·Hugo MouquetMichel C Nussenzweig
Apr 30, 2013·Current Opinion in Chemical Biology·Stanley R Frankel, Patrick A Baeuerle
May 23, 2013·Scientific Reports·Shih-Hsun ChenKonstantinos Konstantopoulos
Jan 21, 2014·Current Opinion in Oncology·Daniel C Christoph, Wilfried E E Eberhardt
Sep 18, 2014·Cancer Research·Teemu T JunttilaAllen Ebens
Sep 19, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Raffit HassanBruce A Wallin
Mar 3, 2015·Drug Discovery Today·Roland E Kontermann, Ulrich Brinkmann
Oct 28, 2015·Cancer Discovery·Aurore MorelloPrasad S Adusumilli
Oct 31, 2015·MAbs·Felix UnverdorbenRoland E Kontermann
Feb 11, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Marina BacacPablo Umana
Sep 1, 2016·Protein Engineering, Design & Selection : PEDS·Tilman SchlothauerEkkehard Mössner
Nov 20, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Raffit HassanIra Pastan
Feb 10, 2017·Clinical Pharmacology and Therapeutics·T YuraszeckJ E Benjamin
Apr 14, 2017·Oncoimmunology·Andres Lopez-AlbaiteroNai-Kong V Cheung
Aug 24, 2017·Pharmacology & Therapeutics·Z Wu, N V Cheung
Oct 6, 2017·Science Translational Medicine·Takahiro IshiguroJunichi Nezu
May 13, 2018·Current Treatment Options in Oncology·Satya DasRichard M Goldberg
Nov 20, 2018·Methods : a Companion to Methods in Enzymology·Christian KleinPablo Umaña
Feb 10, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Akira IizukaYasuto Akiyama
Apr 28, 2019·Pharmacology & Therapeutics·Frans V SuursDerk Jan A de Groot
May 9, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Urs B HagemannAlan S Cuthbertson
Jun 9, 2019·Nature Reviews. Drug Discovery·Aran F LabrijnPaul W H I Parren
Jun 21, 2019·Science Translational Medicine·Alison CrawfordJessica R Kirshner
Jul 30, 2019·Frontiers in Immunology·Joanie Del BanoBrigitte Kerfelec

❮ Previous
Next ❯

Methods Mentioned

BETA
size exclusion chromatography
Assay
Biosensors
Leukapheresis
Xenograft
ELISA
flow cytometry
surface plasmon resonance

Software Mentioned

IncuCyte
GraphPad Prism5
Octet
GraphPad Prism
ForteBio Octet
BLAST
GraphPad

Related Concepts

Related Feeds

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Related Papers

Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme
H Shinmoto, H Murakami
Verhandelingen - Koninklijke Academie voor Geneeskunde van België
K Thielemans
Current Opinion in Molecular Therapeutics
Patrick A BaeuerleRalf Lutterbüse
Advances in Experimental Medicine and Biology
H WangY Guo
© 2021 Meta ULC. All rights reserved